ACADIA Pharmaceuticals Inc. (ACAD) Revenue by Segment & Business Profile
Nuplazid was 59.5% of ACADIA Pharmaceuticals Inc.'s revenue across the 2 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ACADACADIA Pharmaceuticals Inc.Follow ACAD — free
—
Price chart with a free account
- Market cap
- 3.4B
- P/E TTM
- 8.8
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
What the company does
ACADIA Pharmaceuticals Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: Nuplazid (60%), Daybue (40%). Trailing twelve-month revenue: $1.1 billion as of 2026-06-30.
Roles we read
from the filings, not the sector label- Commercial therapies
ACADIA Pharmaceuticals Inc. — questions
- What does ACADIA Pharmaceuticals Inc. do?
- ACADIA Pharmaceuticals Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: Nuplazid (60%), Daybue (40%). Trailing twelve-month revenue: $1.1 billion as of 2026-06-30.
- How does ACADIA Pharmaceuticals Inc. make money?
- By the lines it reports in its SEC filings: Nuplazid 59.5%, Daybue 40.5% of revenue.
Every figure on this page comes from ACADIA Pharmaceuticals Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.